March 20, 2020 07:40 AM EDTUpdated 08:48 AM
Financing
China

In­no­Care IPO over­sub­scribed 300x as Hong Kong in­vestors turned to biotech amid runoff

Jason Mast

Editor

For­get the glob­al stock melt­down. Or at least Chi­nese biotech In­no­Care did, forg­ing ahead with a more than $250-mil­lion IPO in Hong Kong de­spite …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times